Japanese Journal of Clinical Oncology Advance Access originally published online on March 6, 2006
Japanese Journal of Clinical Oncology 2006 36(3):154-158; doi:10.1093/jjco/hyi236
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 Foundation for Promotion of Cancer Research
Fractionated Stereotactic Radiotherapy in Patients with Primary Hepatocellular Carcinoma
1 Department of Radiation Oncology, The Catholic University of Korea, College of Medicine, Seoul, 2 Department of Radiation Oncology, Gyeongsang National University, College of Medicine, Gyeongsang Institute of Health Sciences, Jinju and 3 Department of Radiation Oncology, University of Ulsan, Asan Medical Center, Seoul, Korea
For reprints and all correspondence: Ki Mun Kang, Department of Radiation Oncology, Gyeongsang National University, College of Medicine, Jinju 660-702, South Korea. E-mail: jsk92{at}nongae.gsnu.ac.kr
Received October 19, 2005; accepted December 17, 2005
Objective: The purpose of our study was to evaluate the feasibility and treatment outcomes of fractionated stereotactic radiotherapy (SRT) for primary hepatocellular carcinoma (HCC).
Methods: We enrolled 20 patients who had been histologically diagnosed as HCC patients and treated by fractionated SRT. Tumor size was 2–6.5 cm (average: 3.8 cm). We prescribed 50 Gy in 5 or 10 fractions at the 85–90% isodose line of the planning target volume for 2 weeks. The follow-up period was 3–55 months (median: 23 months).
Results: The overall response rate was 80%, with 4 patients showing complete response (20%), 14 patients showing partial response (60%) and 4 patients showing stable disease (20%). The 1-year and 2-year survival rates were 70.0 and 43.1%, respectively (median: 20 months). The 1-year and 2-year disease-free survival rates were 65.0 and 32.5%, respectively (median: 19 months). The fractionated SRT was well tolerated, because grade 3 or grade 4 toxicity was not observed.
Conclusion: These results suggest that fractionated SRT is a relatively safe and effective method for treating small primary HCC. Thus, fractionated SRT may be suggested as a local treatment of choice for small HCC when the patients are inoperable or when the patients refuse operation.
Key Words: fractionation • hepatocellular carcinoma • stereotactic radiotherapy
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Brada, M. Pijls-Johannesma, and D. De Ruysscher Proton Therapy in Clinical Practice: Current Clinical Evidence J. Clin. Oncol., March 10, 2007; 25(8): 965 - 970. [Full Text] [PDF]
|
|